New! View global litigation for patent families

US3875300A - Composition for sustained release of a medicament and method of using same - Google Patents

Composition for sustained release of a medicament and method of using same Download PDF

Info

Publication number
US3875300A
US3875300A US31617572A US3875300A US 3875300 A US3875300 A US 3875300A US 31617572 A US31617572 A US 31617572A US 3875300 A US3875300 A US 3875300A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
composition
spermicide
medicament
example
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Roger Homm
Gilbert Katz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Abstract

A solid, intimately admixed composition comprising a thermoplastic, physiologically-inert polymer soluble in body fluids, and an effective amount of a suitable medicament. The composition is suitable for introduction into a body cavity, therein to be slowly dissolved by body fluids and release thereby incremental amounts of medicament. Various areas of use include intravaginal applications for spermicidal effect, subcutaneous implantation, and the like.

Description

Homm et al.

Apr. 1, 1975 COMPOSITIN FOR SUSTAINED RELEASE OF A MEDICAMENT AND METHOD OF USING SAME Inventors: Roger Homm, Neshanic; Gilbert Katz, Boonton, both of NJ.

Ortho Pharmaceutical Corporation, Rariton, NJ.

Filed: Dec. 18, 1972 Appl. No.: 316,175

Assignee:

us. c1 ..424/28, 424/27, 128/260, 128/270, 128/271, 128/285 1111. c1 A611 19/00 Field 01 Search 424/27, 28; 128/260, 270, 128/271, 285

References Cited UNlTED STATES PATENTS 12/1962 Morton ct a1 1. 424/28 3,108,043 10/1963 Millman et a1 424/27 X FOREIGN PATENTS OR APPLICATIONS 263,153 3/1960 Australia 722,629 l/1955 United Kingdom 735,370 8/1955 United Kingdom Primary E.\'aminerShep K. Rose Attorney, Agent, or Firm-Benjamin F. Lambert [57] ABSTRACT A solid, intimately admixed compostion comprising a thermoplastic, physiologically-inert polymer soluble in body fluids, andan effective amount of a suitable medicament. The composition is suitable for introduction into a body cavity, therein to be slowly dissolved by body fluids and release thereby incremental amounts of medicament. Various areas of use include intravaginal applications for spermicidal effect, subcutaneous implantation, and the, like.

14 Claims, N0 Drawings COMPOSITIN FOR SUSTAINED RELEASE OF A MEDICAMENT AND METHOD OF USING SAME BACKGROUND OF THE INVENTION The present invention relates to an improved medicament dispensing system of special use in contraception. More particularly it relates to a composition of matter useful for delivering controlled amounts of a medicament within a body cavity at a pre-determined rate.

Delivery of medicaments to a site within a body cavity is usually accomplished either systemically by oral administration or locally by direct introduction into the cavity. The systemic method has the advantage of being convenient, but because it is systemic suffers from side effect" problems. Direct introduction has the advantage of requiring lower doses and is faster acting, but is also usually very inconvenient and quite often unpredictable in efficacy. In this method, the concentration of medicament in the body cavity is not maintained at a constant level, but is rather at a maximum just after application and declines thereafter. Thus, in order to have an effective amount of medicament in the body cavity at all times, it is necessary when using the direct introduction method to give either a moderate excess at short intervals or a large excess at longer intervals. Neither of these alternatives is satisfactorily convenient or economical.

One of the areas of major interest as regards direct introduction of medicaments into body cavities is contraception. Several contraceptive methods are currently employed. For example, there are those which prevent ovulation, those which prevent implantation, and those which prevent sperm from coming in contact with a released ovum. The first method is typified by oral administration of various drugs, usually steroids, and has the disadvantage of being systemic rather than topical. It is advantageous, however, in that administration immediately prior to coitus is not necessary.

The second method is typified by insertion into the uterus and maintenance therein of a foreign object called an intrauterine device. This method has the advantage of the first method and is also topical, but is disadvantageous because of the undesirably high possibility of perforating the uterus. Moreover, the devices are usually painful during the insertion process and usually for long periods thereafter during residency.

A third method usually involves placing some physical or chemical barrier between the sperm and the ovum and is typified by a condom, a spermicidal foam or jelly, and the like, or a combination of two or more of these. This third type has the disadvantage of requiring application just prior to coitus, but has the advantages of being topical in application and having no extravaginal effects. This method would be very desirable indeed if application of the material were required not immediately before coitus but rather at some prior time much in advance of coitus.

The present invention provides a system and method especially suited for contraceptive use of the third type, but capable of broader applications which does not have the disadvantages traditionally associated with it. That is, the invention provides a solid drug delivery system of the type which is inserted into the vagina up to 24 hours prior to coitus and slowly releases a spermicide. The system does not require removal or storage after use since it is soluble in body fluids and is diffused by the system. The present invention, therefore, in its broader aspects provides a solid drug delivery system comprising in intimate admixture a body fluid-soluble, thermoplastic, physiologically-inert polymer and an effective amount ofa suitable medicament. The term medicament includes but is not limited to spermicides, ovacides, antimicrobials, anti-inflammatories, steroidal and non-steroidal anti-fertility agents, prostaglandins, and the like, and includes any compound, drug or medicine having a desired physiological effect.

The polymer may be any of those which are soluble in body fluids such as, for example, a cellulose, a starch, an alginate, a polyvinyl alcohol, a polyvinyl pyrrolidone, a polyacrylamide, an ethyleneoxide polymer, or the like. Preferably, the solubility characteristics of the polymer are chosen so that the entire mass is totally dissolved in the body cavity fluids within a period of about 24 hours so as to give a sustained, prolonged release of medicament. Where vaginal use is contemplated, the preferred polymer is a hydroxypropyl cellulose or hydroxypropylmethyl cellulose having a molecular weight of from 60,000 to 1,000,000. Typically employable here are cellulose ethers having a high degree of ideal propyl substitution at the hydroxyl groups. From to I00 percent propyl substitution is suitable. The product of the invention may be provided in the form of fibers, molded articles or extruded shapes, in which form they may then be placed in the body cavity where they will dissolve and release the medicament at a desirable rate.

The composition of the present invention will contain various amounts of polymer and medicament relative to one another depending upon many factors including the final use to which the composition will be put, the nature of the drug employed, the actual solubility characteristics of the polymer, and the like. In general, however, a composition containing up to about 30 weight percent of the medicament with the balance being essentially polymer will be suitable. Preferably, however, the amount of medicament ranges from 5 to 25 percent by weight based on the weight of the entire composition. Such a formulation is especially suitable for contraceptive use when the composition comprises a spermicide as the medicament and hydroxypropyl cellulose as the polymer.

The compositions of the present invention are prepared by intimately blending the desired polymer in any convenient form such as pellet or powder form with the appropriate amount of medicament. This intimate mixture is then spun, cast, molded, or extruded into fibers or suitable shapes, either with or without the addition of solvents or additional plasticizers.

For example, using hydroxypropyl cellulose as illustrative, a typical preparation is as follows: Hydroxypropyl cellulose powder is intimately mixed with a suitable amount of a medicament, preferably a spermicide. The resulting mixture is melt spun using standard spinning techniques into a strand and the strand chopped into pellets. These pellets are then charged into a standard melt spinning apparatus, are spun into fine fibers and the fibers chopped into lengths convenient for subsequently forming cotton' balls from the fibers. Dry carding techniques are then employed to form cotton balls or wads. There results from this operation the preferred form of the composition of the invention when an intravaginal contraceptive system is sought. The pellets may, on the other hand, be used in the molding or extrusion of a suitable shape, e.g., a circular film, a diaphragm, or the like.

The techniques of fiber formation may vary depending on the particular polymer being used, but these techniques are all within the skill of the art and basically form no part of the present invention. For example, when polyvinyl alcohol is used as the polymer, wet spinning techniques, using an aqueous solution of a suitable coagulating agent, e.g.,'Na SO,, (NH SO MgSO or the like may be employed. Standard wet spinning techniques are also employed when using hydroxypropylmethyl cellulose.

As stated, the preferred composition of the present invention is a mixture of hydroxypropyl cellulose with a spermicide, preferably in the form of a fibrous mass. The spermicide may be any compound known to be spermicidal and compatible with the polymeric system used. Typically acceptable are non-ionic surfactants such as ethoxylated phenoxyethanols. Such materials are well known in the art and are represented by pdiisobutylphenoxypolyethoxy ethanol, known as Triton X-l00, available from Rohm & Haas, Philadelphia, Pa., nonylphenoxypoly(ethoxy),, ethanol (where n is an integer up to 21 and preferably 9), known as Tergitol TP-9 available from Union Carbide, New York, N.Y., also known as Nonoxynol, available from General Aniline & Film Corp., New York, NY. Other spermicides include ricinoleic acid and mercurial salts such as phenyl mercuric acetate. Among the above, the preferred spermicides are the nonylphenoxypoly(ethoxy),, ethanols with that compound wherein n is 9 being most preferred.

The fibrous mass suitably comprises polymerspermicide fibers having a strand diameter of up to 50 denier (about 5.5 mils.) and preferably from 0.0004 to 0.0015 inches, and a strand length of from 0.25 to 2 inches and preferably 0.5 to 1.25 inches. Normally the mass has a bulk density of 0.1 to 0.3 and preferably 0.1 l to 0.15 gms. per cc in the relaxed state. Such dimensions give a product having the appearance of cotton wadding but having sufficient resiliency and elasticity for filling the cross-section of the vaginal canal and providing occlusion of the deep inner recesses and folds, which might otherwise not receive spermicide were a foam, jelly or cream used. Typically, an effective fibrous mass weighs between 0.75 and 1.50 gms. and preferably 1.00 to 1.25 gms. It may be inserted into the vaginal canal using any of the well-known insertion techniques up to 16-24 hours before coitus. A mass of the weight and dimensions described will slowly dissolve over this period in the natural body fluids and will supply an effective dose of spermicide. It thus provides both a physical and chemical barrier to the union of sperm and ovum in a safe, reliable, topical and aesthetic fashion.

Observations of residence times of various embodiments of the present invention in several types of experimental animals (tabulated in FIG. 1) indicate that it has the desired residence time (about 16 hours) in any warm-blooded animal if used at an appropriate dose. For example, fibrous masses weighing 1.00 to 1.25 gms. will have 0.10 to 0.125 gms. of spermicide associated therewith, and this will ordinarily be suitable for virtually complete spermicidal activity over a 16- hour period. Other compositions of the invention, whether fibrous or molded or extruded shapes, behave similarly and are easily adaptable to insertion into any body cavity therein to release drug.

The following examples are given to illustrate specific embodiments of the present invention:

EXAMPLE 1 lnto an oscillating drum mixer are charged 15,2000 gms. of powdered food grade hydroxypropyl cellulose (available under the tradename Klucel G (available from Hercules, lnc., Wilmington, Del., having a molecular weight of 275,000 and an idealized molar substitution of 3.0 and 1,800 gms. of diisobutylphenoxypolyethoxy ethanol, available under the name of Triton X- 100, from Rohm & Haas, Philadelphia, Pa. The blend is intimately mixed and the resulting intimate mixture is charged into a 2-inch Davis-type single screw extruder equipped with a die containing six /s-inch circular orifices. The Extruder has three zones of melting electrically maintained at 325F, 315F, and 330F, respectively. The strands are cooled as they travel down a 30-foot teflon-coated trough, at the end of which is a means for chopping the strands into /2 inch lengths. The resulting pellets are graded for size, the scraps being returned to the extruder for reuse.

The pellets are then re-extruded as above on a l-inch Davis-type extruder equipped with a die containing a 0.018 inch circular orifice and a means for attenuating the strand as it emerges. This monofilament is collected and is chopped into lengths of between about /2 inch and about 2 inches. These lengths are then treated by standard dry-carding techniques to yield fibrous masses of the cotton wad type.

EXAMPLE II The procedure of Example I is repeated except that 15 percent by weight of the spermicide is substituted for the 10 percent used therein.

EXAMPLE "I The procedure of Example 1 is repeated except that 25 percent by weight of the spermicide is substituted for the 10 percent used therein.

EXAMPLE [V The procedure of Example I is repeated except that 5 percent by weight of nonylphenoxypoly(ethoxy),, ethanol, n 9, (available from Union Carbide Corp., New York, N.Y., under the name of Tergitol TP-9) is substituted for the 10 percent by weight of Triton X-100 used therein.

EXAMPLE V The procedure of Example IV is repeated except that 15 percent by weight of spermicide is substituted for the 10 percent used therein.

EXAMPLE VI A wad of fibers as produced in Example 11 and weighing 0.300 gms. is inserted into the vagina of a female rhesus monkey and is observed periodically. Dissolution of the polymer begins immediately and continues until the wad disappears, a period of from about 17 to about 24 hours.

EXAMPLE Vll Into a tank are charged parts by weight of a watersoluble copolymer of polyvinyl alcohol and allyl alcohol prepared in accordance with known techniques, (See Example I of US. Pat. No. 2,909,502), 5 parts by weight of the spermicide Triton X-l (diisobutylphenoxypolyethoxy ethanol) and sufficient water to make a l percent by weight spinning solution of the spermicide mixture. After thorough mixing, filtration, and de-aeration of the spinning solution, fiber is spun from the solution by the wet method, the coagulating solution for which is a 50C aqueous solution containing about 420g/liter of Na SO and having a pH of about 3.9. The monofilament is collected and chopped into staples (-l inch lengths) suitable for formation into cotton balls by standard dry carding techniques.

EXAMPLE VIII The procedure of Example VII is repeated except that 15 percent by weight of spermicide is substituted for the 5 percent used therein.

EXAMPLE IX The procedure of Example VII is repeated except that 25 percent by weight of spermicide is substituted for the 5 percent used therein.

EXAM PLE X The procedure of Example VII is repeated except that 5 percent by weight of Tergitol TP-9 is substituted for the spermicide used therein.

EXAMPLE XI The procedure of Example X is repeated except that 10 percent by weight of spermicide is substituted for the 5 percent used therein.

EXAMPLE XII The procedure of Example X is repeated except that percent by weight of spermicide is substituted for the 5 percent used therein.

EXAMPLE XIII The procedure of Example VII is repeated except that an equal weight ofeach of ricinoleic acid, and phenyl mercuric acetate is substituted for the 5 percent by weight of Triton X-l00 used therein.

EXAMPLE XIV Several fibers as produced in Example II are dissolved in saline solution and are added to rabbit semen samples in vitro. Immobilization of the sperm is observed to occur. Similar results are obtained when the fibers of Examples l-XIV are utilized in this manner.

What is claimed is:

l. A composition of matter comprising an intimate admixture of a thermoplastic, physiologically-inert hydroxypropyl cellulose or hydroxypropylmethyl cellulose polymer soluble in vaginal fluids shaped as an intra-vaginal medicament applicator and up to 30 weight percent of a vaginal medicament, said intimate mixture having been melt spun by being melted, spun, cast, molded or extruded in the molten state into a fibrous mass of fine fibers, strands, pellets, balls or wads, the entire mass totally dissolving in said vaginal fluid within about 24 hours.

2. The composition of claim 1 wherein the polymer is hydroxypropyl cellulose.

3. The composition of claim 2 in which the medicament is a spermicide, ovacide, antimicrobial, prostaglandin, steroidal or non-steroidal antifertility agent.

4. The composition of claim 3 wherein the medicament is a spermicide.

5. The composition of claim 4 wherein the spermicide is present in an amount ranging from 5 to 25 percent by weight based on the weight of the entire composition.

6. The composition of claim wherein the polymer is a hydroxypropyl cellulose.

7. The composition of claim 6 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol wherein n is 9.

8. The composition of claim 6 wherein the spermicide is p-diisobutylphenoxypolyethoxy ethanol.

9. The composition of claim 5 wherein the polymer is a hydroxypropylmethyl cellulose.

10. The composition of claim 9 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol or pdiisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.

11. The composition ofclaim 6 wherein the composition is in the form of a fibrous mass having a fiber diameter of from 0.0004 to 0.0015 inches, and a bulk density of from 0.1 l to 0.15 gms. per cubic cm.

12. The composition of claim 11 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol or pdiisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.

13. The method for delivering a vaginal medicament to a site within the vagina from a solid medicament delivery system which comprises introducing within the vagina an effective amount of the composition of claim 1.

14. The method of claim 13 wherein the composition employed is from 5 to 25 percent by weight ofa spermicide admixed in a hydroxypropyl cellulose.

1 UNITED STATES PATENT OFFICE tmwmmm Patent No. 3, 75,3 Dated Ap l 975 Inventor(s) Roger Homm and Gilbert Katz It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

rm n w Page 1, in Title, COMPOSITIN should read COMPOSITION In Column 1, line 1, in Title, "COMPOSI'IIN" should read COWOSITION Q In Column 2, line 7, "anti-fertility" should read antifertility In (301 2 line 63, The word cotton should be in quotation marks.

In Column bline 10, "Wilmin ton, Del., having" should read Wilmington, Del.), having igntd an said this fifth Day of August 1975 [SEAL] Arrest.-

RUTH C. MASON C. MARSHALL DANN Allvsring ()jficer ('mnmissimwr of Iarenrs and Trademarks Li J

Claims (14)

1. A COMPOSITION OF MATTER COMPRISING AN INTIMATE ADMIXTURE OF A THERMOPLASTIC PHYSIOLOGICALLY-INERT HYDROXYPROPYL CELLULOSE OR HYDROXYPROPYLMETHYL CELLULOSE POLYMER SLUBLE IN VAGINAL FLUIDS SHAPED AS AN INTRA-VAGINAL MEDICAMENT APPLICATOR AND UP TO 30 WEIGHT PERCENT OF A VAGINAL MEDICAMENT APPLICAINTIMATE MIXTURE HAVING BEEN MELT SPUN BY BEING MELTED, SPUN, CAST MOLDED OR EXTRUDED IN THE MOLTEN STATE INTO A FIBROUS MASS OF FINE FIBERS, STRANDS, PELLETS, BALLS OR WADS THE ENTIRE MASS TOTALLY DISSOLVING IN SAID VAGINAL WITHIN ABOUT 24 HOURS.
2. The composition of claim 1 wherein the polymer is hydroxypropyl cellulose.
3. The composition of claim 2 in which the medicament is a spermicide, ovacide, antimicrobial, prostaglandin, steroidal or non-steroidal antifertility agent.
4. The composition of claim 3 wherein the medicament is a spermicide.
5. The composition of claim 4 wherein the spermicide is present in an amount ranging from 5 to 25 percent by weight based on the weight of the entire composition.
6. The composition of claim 5 wherein the polymer is a hydroxypropyl cellulose.
7. The composition of claim 6 wherein the spermicide is nonylphenoxypoly(ethoxy)n ethanol wherein n is 9.
8. The composition of claim 6 wherein the spermicide is p-diisobutylphenoxypolyethoxy ethanol.
9. The composition of claim 5 wherein the polymer is a hydroxypropylmethyl cellulose.
10. The composition of claim 9 wherein the spermicide is nonylphenoxypoly(ethoxy)n ethanol or p-diisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.
11. The composition of claim 6 wherein the composition is in the form of a fibrous mass having a fiber diameter of from 0.0004 to 0.0015 inches, and a bulk density of from 0.11 to 0.15 gms. per cubic cm.
12. The composition of claim 11 wherein the spermicide is nonylphenoxypoly(ethoxy)n ethanol or p-diisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.
13. The method for delivering a vaginal medicament to a site within the vagina from a solid medicament delivery system which comprises introducing within the vagina an effective amount of the composition of claim 1.
14. The method of claim 13 wherein the composition employed is from 5 to 25 percent by weight of a spermicide admixed in a hydroxypropyl cellulose.
US3875300A 1972-12-18 1972-12-18 Composition for sustained release of a medicament and method of using same Expired - Lifetime US3875300A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US3875300A US3875300A (en) 1972-12-18 1972-12-18 Composition for sustained release of a medicament and method of using same

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3875300A US3875300A (en) 1972-12-18 1972-12-18 Composition for sustained release of a medicament and method of using same
FR7344027A FR2210415B1 (en) 1972-12-18 1973-12-10
GB5704473A GB1446626A (en) 1972-12-18 1973-12-10 Composition for sustained release of a medicament and method of using same
BE138771A BE808519A (en) 1972-12-18 1973-12-11 Medicament for loosening maintained an active ingredient and method of using this drug
JP13971573A JPS49133519A (en) 1972-12-18 1973-12-17
DE19732362991 DE2362991A1 (en) 1972-12-18 1973-12-18 Arzneipraeparate for direct einfuehrung in body cavity
NL7317324A NL7317324A (en) 1972-12-18 1973-12-18

Publications (1)

Publication Number Publication Date
US3875300A true US3875300A (en) 1975-04-01

Family

ID=23227840

Family Applications (1)

Application Number Title Priority Date Filing Date
US3875300A Expired - Lifetime US3875300A (en) 1972-12-18 1972-12-18 Composition for sustained release of a medicament and method of using same

Country Status (7)

Country Link
US (1) US3875300A (en)
JP (1) JPS49133519A (en)
BE (1) BE808519A (en)
DE (1) DE2362991A1 (en)
FR (1) FR2210415B1 (en)
GB (1) GB1446626A (en)
NL (1) NL7317324A (en)

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50105814A (en) * 1973-12-17 1975-08-20
US3946734A (en) * 1975-02-19 1976-03-30 The United States Of America As Represented By The Secretary Of State Apparatus for controlling the release of a drug
US3982537A (en) * 1974-12-30 1976-09-28 Louis Bucalo Dynamic implants and method for implanting the same
US4045558A (en) * 1975-10-08 1977-08-30 Merck & Co., Inc. Pilocarpine salts
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4136145A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
DE2940146A1 (en) * 1978-10-17 1980-04-30 Stolle Res & Dev Microparticles for treatment of internal female reproductive and their use
EP0016051A1 (en) * 1978-06-09 1980-10-01 Donald, Enterprises, Inc. Contraceptive-antivenereal disease tampon
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4265875A (en) * 1976-07-23 1981-05-05 Inveresk Research International Controlled release suppositories
US4287175A (en) * 1978-06-22 1981-09-01 Merck & Co., Inc. Contact lens wetting agents
US4309997A (en) * 1978-06-09 1982-01-12 Donald Jack W Contraceptive and/or antivenereal disease tampon
US4343787A (en) * 1975-07-29 1982-08-10 Merck & Co., Inc. Shaped ophthalmic inserts for treating dry eye syndrome
US4344968A (en) * 1978-12-09 1982-08-17 Nippon Kayaku Kabushiki Kaisha Pharmaceutical vehicle
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4673565A (en) * 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
EP0250125A2 (en) * 1986-06-03 1987-12-23 Smith & Nephew plc Drug delivery device, its preparation and use
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
WO1988008298A1 (en) * 1987-04-20 1988-11-03 Fuisz Richard C Rapidly dissoluble medicinal dosage unit and method of manufacture
WO1988008296A1 (en) * 1987-04-20 1988-11-03 Fuisz Richard C A spun fibrous cosmetic and method of use
US4841968A (en) * 1986-09-26 1989-06-27 Southern Research Institute Antithrombotic/thrombolytic suture and methods of making and using the same
WO1990011017A1 (en) * 1989-03-20 1990-10-04 Fuisz Pharmaceutical Ltd. A moderated spun fibrous system and method of manuacture
US4997856A (en) * 1987-04-20 1991-03-05 Fuisz Pharmaceutical Ltd. Method of producing compacted dispersable systems
US5236734A (en) * 1987-04-20 1993-08-17 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
US5238696A (en) * 1987-04-20 1993-08-24 Fuisz Technologies Ltd. Method of preparing a frozen comestible
US5268110A (en) * 1991-05-17 1993-12-07 Fuisz Technologies Ltd. Oil removing method
US5279849A (en) * 1992-05-12 1994-01-18 Fuisz Technologies Ltd. Dispersible polydextrose, compositions containing same and method for the preparation thereof
US5286513A (en) * 1987-04-20 1994-02-15 Fuisz Technologies Ltd. Proteinaceous food product containing a melt spun oleaginous matrix
US5348758A (en) * 1992-10-20 1994-09-20 Fuisz Technologies Ltd. Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5380529A (en) * 1990-07-10 1995-01-10 Laboratoire Lucchini S.A. Pharmaceutical, vaginal applicable preparation and a process for its preparation
US5380473A (en) * 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
US5387431A (en) * 1991-10-25 1995-02-07 Fuisz Technologies Ltd. Saccharide-based matrix
US5407676A (en) * 1990-12-14 1995-04-18 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and a method of manufacture
US5427804A (en) * 1992-03-05 1995-06-27 Fuisz Technologies Ltd. Low-fat edible proteins with maltodextrins and low-saturate oils
US5445769A (en) * 1994-06-27 1995-08-29 Fuisz Technologies Ltd. Spinner head for flash flow processing
US5456932A (en) * 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
US5472731A (en) * 1987-04-20 1995-12-05 Fuisz Technologies Ltd. Protein based food product
US5501858A (en) * 1992-05-12 1996-03-26 Fuisz Technologies Ltd. Rapidly dispersable compositions containing polydextrose
US5512289A (en) * 1993-07-28 1996-04-30 Johnson & Johnson Consumer Products, Inc. Spermicidal anti-viral lubricant composition and method of using same
US5516537A (en) * 1987-04-20 1996-05-14 Fuisz Technologies Ltd. Frozen comestibles
US5518551A (en) * 1993-09-10 1996-05-21 Fuisz Technologies Ltd. Spheroidal crystal sugar and method of making
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5520859A (en) * 1993-10-07 1996-05-28 Fuisz Technologies Ltd. Method for flash flow processing having feed rate control
US5545615A (en) * 1987-09-18 1996-08-13 Zymogenetics, Inc. A method of inhibiting fertilization by alpha-1-antitrypsin or antithrombin III
US5549917A (en) * 1994-07-01 1996-08-27 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5556652A (en) * 1994-08-05 1996-09-17 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5576042A (en) * 1991-10-25 1996-11-19 Fuisz Technologies Ltd. High intensity particulate polysaccharide based liquids
US5587198A (en) * 1995-05-31 1996-12-24 Fuisz Technologies Ltd. Positive hydration method of preparing confectionery and product therefrom
US5593502A (en) * 1993-10-07 1997-01-14 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5624684A (en) * 1991-05-17 1997-04-29 Fuisz Technologies Ltd. Enzyme systems
US5651987A (en) * 1991-12-17 1997-07-29 Fuisz Technologies Ltd. Ulcer prevention and treatment composition
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
US5728397A (en) * 1992-05-12 1998-03-17 Fuisz Technologies Ltd. Polydextrose product and process
US5843922A (en) * 1994-07-29 1998-12-01 Fuisz Technologies Ltd. Preparation of oligosaccharides and products therefrom
US5851553A (en) * 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) * 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US6020002A (en) * 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
US20040131664A1 (en) * 2003-01-03 2004-07-08 Mo Y. Joseph Topical stabilized prostaglandin E compound dosage forms
US20120058166A1 (en) * 2010-07-02 2012-03-08 Glenn Jr Robert Wayne Filaments comprising a non-perfume active agent nonwoven webs and methods for making same
US20130136784A1 (en) * 2007-10-11 2013-05-30 Robert J. Staab Methods for delivery of medication using dissolvable devices

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2041220B (en) * 1979-01-29 1983-07-27 Perstorp Ab Medical preparations containing prostaglandins
JPH0132205B2 (en) * 1979-08-31 1989-06-29 Ono Pharmaceutical Co
JPS6222965B2 (en) * 1981-08-20 1987-05-20 Shinetsu Chem Ind Co
JPS58206512A (en) * 1982-05-27 1983-12-01 Chiyandora Uijiyaya Female external contraception membrane
ES2017282A6 (en) * 1989-07-28 1991-01-16 Aguilera Franco Maria Dressing applications transcutaneous active substances for therapeutic or cosmetic purposes.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067743A (en) * 1958-11-12 1962-12-11 Alginate Ind Ltd Alginic compounds
US3108043A (en) * 1960-05-09 1963-10-22 Ortho Pharma Corp Spermicidal sheet-like material

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067743A (en) * 1958-11-12 1962-12-11 Alginate Ind Ltd Alginic compounds
US3108043A (en) * 1960-05-09 1963-10-22 Ortho Pharma Corp Spermicidal sheet-like material

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50105814A (en) * 1973-12-17 1975-08-20
JPS5636173B2 (en) * 1973-12-17 1981-08-22
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
US4136145A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US3982537A (en) * 1974-12-30 1976-09-28 Louis Bucalo Dynamic implants and method for implanting the same
US3946734A (en) * 1975-02-19 1976-03-30 The United States Of America As Represented By The Secretary Of State Apparatus for controlling the release of a drug
US4343787A (en) * 1975-07-29 1982-08-10 Merck & Co., Inc. Shaped ophthalmic inserts for treating dry eye syndrome
US4045558A (en) * 1975-10-08 1977-08-30 Merck & Co., Inc. Pilocarpine salts
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4292300A (en) * 1976-07-23 1981-09-29 Inveresk Research International Controlled release suppositories
US4265875A (en) * 1976-07-23 1981-05-05 Inveresk Research International Controlled release suppositories
EP0016051A1 (en) * 1978-06-09 1980-10-01 Donald, Enterprises, Inc. Contraceptive-antivenereal disease tampon
US4309997A (en) * 1978-06-09 1982-01-12 Donald Jack W Contraceptive and/or antivenereal disease tampon
US4287175A (en) * 1978-06-22 1981-09-01 Merck & Co., Inc. Contact lens wetting agents
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
DE2940146A1 (en) * 1978-10-17 1980-04-30 Stolle Res & Dev Microparticles for treatment of internal female reproductive and their use
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
US4344968A (en) * 1978-12-09 1982-08-17 Nippon Kayaku Kabushiki Kaisha Pharmaceutical vehicle
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4673565A (en) * 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
US4784857A (en) * 1986-06-03 1988-11-15 Smith And Nephew Associated Companies Plc Drug delivery device, its preparation and use
EP0250125A3 (en) * 1986-06-03 1989-04-19 Smith And Nephew Associated Companies P.L.C. Drug delivery device, its preparation and use
EP0250125A2 (en) * 1986-06-03 1987-12-23 Smith & Nephew plc Drug delivery device, its preparation and use
US4841968A (en) * 1986-09-26 1989-06-27 Southern Research Institute Antithrombotic/thrombolytic suture and methods of making and using the same
WO1988008296A1 (en) * 1987-04-20 1988-11-03 Fuisz Richard C A spun fibrous cosmetic and method of use
WO1988008298A1 (en) * 1987-04-20 1988-11-03 Fuisz Richard C Rapidly dissoluble medicinal dosage unit and method of manufacture
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US4873085A (en) * 1987-04-20 1989-10-10 Fuisz Pharmaceutical Ltd. Spun fibrous cosmetic and method of use
US5516537A (en) * 1987-04-20 1996-05-14 Fuisz Technologies Ltd. Frozen comestibles
US5503862A (en) * 1987-04-20 1996-04-02 Fuisz Technologies Ltd. Method of subjecting a protein-containing material to flash flow processing and product thereof
US4997856A (en) * 1987-04-20 1991-03-05 Fuisz Pharmaceutical Ltd. Method of producing compacted dispersable systems
US5236734A (en) * 1987-04-20 1993-08-17 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
US5238696A (en) * 1987-04-20 1993-08-24 Fuisz Technologies Ltd. Method of preparing a frozen comestible
US5490993A (en) * 1987-04-20 1996-02-13 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun matrix and product thereof
US5456932A (en) * 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
US5286513A (en) * 1987-04-20 1994-02-15 Fuisz Technologies Ltd. Proteinaceous food product containing a melt spun oleaginous matrix
US5472731A (en) * 1987-04-20 1995-12-05 Fuisz Technologies Ltd. Protein based food product
US5374447A (en) * 1987-04-20 1994-12-20 Fuisz Technologies Ltd. Method of preparing a reduced-fat meat product
EP0357665A1 (en) * 1987-04-20 1990-03-14 Fuisz Pharmaceutical Ltd Rapidly dissoluble medicinal dosage unit and method of manufacture.
US5545615A (en) * 1987-09-18 1996-08-13 Zymogenetics, Inc. A method of inhibiting fertilization by alpha-1-antitrypsin or antithrombin III
WO1990011017A1 (en) * 1989-03-20 1990-10-04 Fuisz Pharmaceutical Ltd. A moderated spun fibrous system and method of manuacture
US5380529A (en) * 1990-07-10 1995-01-10 Laboratoire Lucchini S.A. Pharmaceutical, vaginal applicable preparation and a process for its preparation
US5407676A (en) * 1990-12-14 1995-04-18 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and a method of manufacture
US5624684A (en) * 1991-05-17 1997-04-29 Fuisz Technologies Ltd. Enzyme systems
US6129926A (en) * 1991-05-17 2000-10-10 Fuisz Technologies Ltd. Flash flow processing of thermoplastic polymers and products made therefrom
US5268110A (en) * 1991-05-17 1993-12-07 Fuisz Technologies Ltd. Oil removing method
US5709876A (en) * 1991-10-25 1998-01-20 Fuisz Technologies Ltd. Saccharide-based matrix
US5429836A (en) * 1991-10-25 1995-07-04 Fuisz Technologies Ltd. Saccharide-based matrix
US5597608A (en) * 1991-10-25 1997-01-28 Fuisz Technologies Ltd. Saccharide-based matrix incorporating maltodextrin and process for making
US5576042A (en) * 1991-10-25 1996-11-19 Fuisz Technologies Ltd. High intensity particulate polysaccharide based liquids
US5387431A (en) * 1991-10-25 1995-02-07 Fuisz Technologies Ltd. Saccharide-based matrix
US5651987A (en) * 1991-12-17 1997-07-29 Fuisz Technologies Ltd. Ulcer prevention and treatment composition
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
US5427804A (en) * 1992-03-05 1995-06-27 Fuisz Technologies Ltd. Low-fat edible proteins with maltodextrins and low-saturate oils
US5501858A (en) * 1992-05-12 1996-03-26 Fuisz Technologies Ltd. Rapidly dispersable compositions containing polydextrose
US5728397A (en) * 1992-05-12 1998-03-17 Fuisz Technologies Ltd. Polydextrose product and process
US5279849A (en) * 1992-05-12 1994-01-18 Fuisz Technologies Ltd. Dispersible polydextrose, compositions containing same and method for the preparation thereof
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5348758A (en) * 1992-10-20 1994-09-20 Fuisz Technologies Ltd. Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5380473A (en) * 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
US5512289A (en) * 1993-07-28 1996-04-30 Johnson & Johnson Consumer Products, Inc. Spermicidal anti-viral lubricant composition and method of using same
US5827563A (en) * 1993-09-10 1998-10-27 Fuisz Technologies Ltd. Spheroidal crystal sugar
US5895664A (en) * 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5871781A (en) * 1993-09-10 1999-02-16 Fuisz Technologies Ltd. Apparatus for making rapidly-dissolving dosage units
US5518551A (en) * 1993-09-10 1996-05-21 Fuisz Technologies Ltd. Spheroidal crystal sugar and method of making
US5851553A (en) * 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5601076A (en) * 1993-09-10 1997-02-11 Fuisz Technologies Ltd. Spheroidal crystal sugar and method of making
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5866163A (en) * 1993-09-10 1999-02-02 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5597416A (en) * 1993-10-07 1997-01-28 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5520859A (en) * 1993-10-07 1996-05-28 Fuisz Technologies Ltd. Method for flash flow processing having feed rate control
US5593502A (en) * 1993-10-07 1997-01-14 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5851552A (en) * 1994-06-14 1998-12-22 Fuisz Technologies, Ltd. Delivery of controlled-release system(s)
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5733577A (en) * 1994-06-14 1998-03-31 Fuisz Technologies Ltd. Delivery of controlled-release system (s)
US6020002A (en) * 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
US5853762A (en) * 1994-06-14 1998-12-29 Fuisz Technologies Ltd Delivery of controlled-release system(s)
US5445769A (en) * 1994-06-27 1995-08-29 Fuisz Technologies Ltd. Spinner head for flash flow processing
US5549917A (en) * 1994-07-01 1996-08-27 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5824342A (en) * 1994-07-01 1998-10-20 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5582855A (en) * 1994-07-01 1996-12-10 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5843922A (en) * 1994-07-29 1998-12-01 Fuisz Technologies Ltd. Preparation of oligosaccharides and products therefrom
US5556652A (en) * 1994-08-05 1996-09-17 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5744180A (en) * 1994-08-05 1998-04-28 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5633027A (en) * 1994-08-05 1997-05-27 Fuisz Technologies Ltd. Confectioneries containing stabilized highly odorous flavor component delivery systems
US5587198A (en) * 1995-05-31 1996-12-24 Fuisz Technologies Ltd. Positive hydration method of preparing confectionery and product therefrom
US5804247A (en) * 1995-05-31 1998-09-08 Fuisz Technologies Ltd. Positive hydration method of preparing confectionary and product therefrom
US20040131664A1 (en) * 2003-01-03 2004-07-08 Mo Y. Joseph Topical stabilized prostaglandin E compound dosage forms
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US20130136784A1 (en) * 2007-10-11 2013-05-30 Robert J. Staab Methods for delivery of medication using dissolvable devices
US20120058166A1 (en) * 2010-07-02 2012-03-08 Glenn Jr Robert Wayne Filaments comprising a non-perfume active agent nonwoven webs and methods for making same

Also Published As

Publication number Publication date Type
NL7317324A (en) 1974-06-20 application
BE808519A1 (en) grant
DE2362991A1 (en) 1974-06-20 application
BE808519A (en) 1974-06-11 grant
GB1446626A (en) 1976-08-18 application
JPS49133519A (en) 1974-12-21 application
FR2210415B1 (en) 1977-04-15 grant
FR2210415A1 (en) 1974-07-12 application

Similar Documents

Publication Publication Date Title
US3424158A (en) Combination plastic mold,suppository package,dispenser and method for providing and using the same
US3108046A (en) Method of preparing high dosage sustained release tablet and product of this method
US5346703A (en) Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US4131648A (en) Structured orthoester and orthocarbonate drug delivery devices
US4185618A (en) Promotion of fibrous tissue growth in fallopian tubes for female sterilization
US4093709A (en) Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US5071644A (en) Topical drug delivery with thermo-irreversible gels
Beck et al. A new long-acting injectable microcapsule system for the administration of progesterone
US3911911A (en) Anti-fertility device
US4111201A (en) Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4111202A (en) Osmotic system for the controlled and delivery of agent over time
US4177256A (en) Osmotic bursting drug delivery device
US3995631A (en) Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US6372245B1 (en) Plasticized bioerodible controlled delivery system
US3760806A (en) Helical osmotic dispenser with non-planar membrane
US5518731A (en) Nonaqueous fluorinated drug delivery vehicle suspensions
US5088505A (en) Contraceptive implant
US4292965A (en) Intravaginal ring
US4327725A (en) Osmotic device with hydrogel driving member
US4764377A (en) Intra-pocket drug delivery devices for treatment of periodontal diseases
US5035891A (en) Controlled release subcutaneous implant
US4613497A (en) Dry, water-foamable pharmaceutical compositions
US3760984A (en) Osmotically powered agent dispensing device with filling means
US5124151A (en) Drug delivery by injection with thermo-irreversible gels
US2793979A (en) Method of making a sustained release pharmaceutical tablet and product of the method